Marksans Pharma Shares Surge 9% on US FDA Approval of Pain Relief Tablet

Marksans Pharma Ltd (NSE: MARKSANS; BSE:524404) announced that it has received final approval from the US Food and Drug Administration (“FDA”) for its Abbreviated New Drug Application (“ANDA”) for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg, over the counter (“OTC”) bioequivalent of Advil Dual Action Tablets 250 mg/125 mg. 

The Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC) are bioequivalent to the reference listed drug (RLD), Advil Dual Action of GlaxoSmithKline Consumer Healthcare Holdings (US) LLC. Advil Dual Action was first available as an over-the-counter drug in 2020. Owning to the positive sentiment, the stock gained more than 9% to make a fresh 52-week high. 

Marksans Pharma Limited headquartered in Mumbai, India is engaged in the Research, Manufacturing & Marketing of generic pharmaceutical formulations in the global markets. The company’s manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA, and Australian TGA. The company’s robust product portfolio spreads over major therapeutic segments of CVS, CNS, Antidiabetic, Pain Management, Gastroenterological, and Anti-allergies. The company is marketing these products globally. 

Today, the stock opened at Rs 93.42, with a high and low of Rs 103 and Rs 93.42. Currently, the stock is trading at Rs 101.90. up by 9.09%. 

In the last six months, the shares of the company have given about 50% returns, and in the last one year, the stock has given about 109% returns.  

The stock has a 52-week high of Rs 103 and a 52-week low of Rs 45.65. The company has a ROCE of 22.5% and an ROE of 18.6% with a market capitalisation of Rs 4,636 crore. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet, and is subject to changes. Please consult an expert before making related decisions.